235 related articles for article (PubMed ID: 27898496)
21. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
22. Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder.
Evans EA; Yoo C; Huang D; Saxon AJ; Hser YI
J Subst Abuse Treat; 2019 Nov; 106():19-28. PubMed ID: 31540607
[TBL] [Abstract][Full Text] [Related]
23. Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder.
Rudolph KE; Williams NT; Goodwin ATS; Shulman M; Fishman M; Díaz I; Luo S; Rotrosen J; Nunes EV
Drug Alcohol Depend; 2022 Oct; 239():109609. PubMed ID: 36075154
[TBL] [Abstract][Full Text] [Related]
24. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
[TBL] [Abstract][Full Text] [Related]
25. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
26. Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial.
Bastien G; Abboud A; McAnulty C; Elkrief L; Ledjiar O; Socias ME; Le Foll B; Bahji A; Brissette S; Marsan S; Jutras-Aswad D
J Dual Diagn; 2024; 20(3):189-200. PubMed ID: 38580298
[TBL] [Abstract][Full Text] [Related]
27. Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies.
Betts KS; Chan G; McIlwraith F; Dietze P; Whittaker E; Burns L; Alati R
Addiction; 2016 Jul; 111(7):1214-23. PubMed ID: 26857811
[TBL] [Abstract][Full Text] [Related]
28. Determinants of selection into buprenorphine/naloxone among people initiating opioid agonist treatment in British Columbia.
Homayra F; Hongdilokkul N; Piske M; Pearce LA; Zhou H; Min JE; Krebs E; Nosyk B
Drug Alcohol Depend; 2020 Feb; 207():107798. PubMed ID: 31927163
[TBL] [Abstract][Full Text] [Related]
29. Patient Satisfaction With Standard Methadone and Flexible Buprenorphine/Naloxone Models of Care: Results From a Pragmatic Randomized Controlled Clinical Trial.
Hassan AN; Bozinoff N; Jutras-Aswad D; Socias ME; Stewart SH; Lim R; Le Foll B;
J Addict Med; 2023 Jan-Feb 01; 17(1):e49-e56. PubMed ID: 35916430
[TBL] [Abstract][Full Text] [Related]
30. Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use Disorder.
Shulman M; Luo SX; Campbell ANC; Scodes J; Pavlicova M; Broffman A; Saxon AJ; Nunes EV
J Addict Med; 2020; 14(5):e188-e194. PubMed ID: 32039934
[TBL] [Abstract][Full Text] [Related]
31. Buprenorphine alone or with naloxone: Which is safer?
Kelty E; Cumming C; Troeung L; Hulse G
J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
[TBL] [Abstract][Full Text] [Related]
32. Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain.
Worley MJ; Heinzerling KG; Shoptaw S; Ling W
Exp Clin Psychopharmacol; 2015 Dec; 23(6):428-35. PubMed ID: 26302337
[TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada.
Piske M; Thomson T; Krebs E; Hongdilokkul N; Bruneau J; Greenland S; Gustafson P; Karim ME; McCandless LC; Maclure M; Platt RW; Siebert U; Socías ME; Tsui JI; Wood E; Nosyk B
BMJ Open; 2020 Sep; 10(9):e036102. PubMed ID: 32912944
[TBL] [Abstract][Full Text] [Related]
34. Randomized clinical trial comparing buprenorphine/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction.
Neumann AM; Blondell RD; Hoopsick RA; Homish GG
J Addict Dis; 2020; 38(1):33-41. PubMed ID: 31774028
[TBL] [Abstract][Full Text] [Related]
35. Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Moore K; Magee M; Sevinsky H; Chang M; Lubin S; Myers E; Ackerman P; Llamoso C
Br J Clin Pharmacol; 2019 Aug; 85(8):1771-1780. PubMed ID: 30980734
[TBL] [Abstract][Full Text] [Related]
36. Methadone and buprenorphine treatments in patients with schizophrenia.
Dervaux A; Plancke L; Amariei A; Trouiller P; Tahon M; Martinetti MP; Naassila M; Cottencin O; Danel T
Schizophr Res; 2019 Jul; 209():286-288. PubMed ID: 31101511
[No Abstract] [Full Text] [Related]
37. The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial.
Bahji A; Bastien G; Bach P; Choi J; Le Foll B; Lim R; Jutras-Aswad D; Socias ME
Can J Psychiatry; 2024 Mar; 69(3):172-182. PubMed ID: 37697811
[TBL] [Abstract][Full Text] [Related]
38. Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study.
Hoffman K; Peyton ML; Sumner M
J Addict Med; 2017; 11(3):217-223. PubMed ID: 28353467
[TBL] [Abstract][Full Text] [Related]
39. Trajectories of drug treatment and illicit opioid use in the AIDS Linked to the IntraVenous Experience cohort, 2014-2019.
Rudolph JE; Cepeda JA; Astemborski J; Kirk GD; Mehta SH; Genberg BL
Int J Drug Policy; 2023 Aug; 118():104120. PubMed ID: 37429162
[TBL] [Abstract][Full Text] [Related]
40. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
